Baseline characteristics of patients treated with cyclosporine, adalimumab, or combination of the 2 for active psoriatic arthritis (PsA) despite methotrexate therapy.
| Characteristic | Cyclosporine, n = 57, mean ± SD | Adalimumab, n = 58, mean ± SD | Combination, n = 55, mean ± SD |
|---|---|---|---|
| Age, yrs | 45.9 ± 12.8 | 46.8 ± 14.1 | 45.9 ± 14.4 |
| Female sex, % | 49.1 | 55.2 | 56.4 |
| Psoriasis duration, yrs | 8.0 ± 11.3 | 7.8 ± 12.1 | 8.1 ± 11.5 |
| PsA duration, yrs since first articular manifestation* | 4.0 (1.0–10.0) | 4.0 (1.0–10.0) | 2.0 (1.0–5.0) |
| Early disease (< 2 yrs), % | 40.4 | 43.1 | 54.6 |
| Previous methotrexate dosage, mg* | 15.0 (12.5–20.0) | 15.0 (12.5–17.5) | 15.0 (12.5–20.0) |
| Tender joints, n** | 9.7 ± 8.0 | 13.0 ± 10.0 | 14.5 ± 11.7 |
| Swollen joints, n | 6.7 ± 6.5 | 7.8 ± 6.4 | 9.4 ± 9.6 |
| Pain, VAS, mm | 50.2 ± 23.0 | 58.6 ± 22.4 | 54.7 ± 23.2 |
| Patient global, VAS, mm | 51.6 ± 23.5 | 59.7 ± 21.9 | 57.0 ± 21.1 |
| Physician global, VAS, mm | 50.3 ± 23.4 | 57.3 ± 22.2 | 52.5 ± 18.8 |
| HAQ*** | 1.01 ± 0.6 | 1.28 ± 0.7 | 1.35 ± 0.6 |
| PASI | 16.5 ± 12.0 (n = 41) | 14.1 ± 13.1 (n = 43) | 15.7 ± 11.1 (n = 44) |
| ESR, mm/h | 40.3 ± 23.5 | 50.3 ± 22.7 | 47.1 ± 23.9 |
| CRP, mg/dl | 15.9 ± 18.1 | 24.1 ± 22.1 | 18.7 ± 15.9 |
| Axial involvement, % | 11 | 12 | 12 |
| RF+, % | 11 | 12 | 10 |
| ACPA+, % | 5 | 6 | 6 |
| HLA-B27+, % | 23 | 23 | 24 |
| Systemic steroids, % | 24 | 23 | 23 |
↵* Values without a normal distribution are expressed as median (25th–75th percentile).
↵** p = 0.0364.
↵*** p = 0.0086. RF: rheumatoid factor; ACPA: anticitrullinated protein antibodies; VAS: visual analog scale; PASI: Psoriasis Area and Severity Index; HAQ: Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.